Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bicara Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bicara Therapeutics's regulatory disclosures and financial reporting.
Ryan Cohlhepp, President and COO and a director of Bicara Therapeutics, Inc. (BCAX), reported multiple stock and option transactions executed pursuant to a Rule 10b5-1 trading plan adopted on 02/12/2025. On 10/06/2025 and 10/07/2025, the reporting person acquired options exercisable at $3.7898 and recorded option-based increases of 24,000 and 8,000 option rights. Offsetting sales were reported across the same dates totaling 50,500 common shares sold at weighted-average prices around $18.06. Following these transactions the reporting person beneficially owned 202,641 shares of common stock. The Form 4 discloses that vesting of the option shares occurs in sixteen quarterly installments following 08/08/2023.
Bicara Therapeutics, Inc. (BCAX) filing a Form 144 discloses a proposed sale of 5,627 common shares with an aggregate market value of $102,242 on 10/08/2025 through UBS Financial Services on NASDAQ. The filing states these shares were acquired the same day, 10/08/2025, by exercise of stock options and paid in cash.
The notice also lists recent sales by the same person: 6,514 shares on 10/06/2025 for $118,356.12 and 18,244 shares on 10/07/2025 for $332,385.61. The filer affirms they do not possess undisclosed material adverse information and includes the standard Rule 10b5-1 representation language where applicable.
Bicara Therapeutics, Inc. (BCAX) filed a Form 144 notice reporting a proposed sale of 18,244 common shares through UBS Financial Services with an aggregate market value of $328,392.00. The filing states the shares were acquired and are to be sold on 10/07/2025 following an exercise of stock options, with payment in cash.
The notice also discloses a prior sale by the same person: 6,514 shares sold on 10/06/2025 for gross proceeds of $118,356.12. The filer certifies no undisclosed material adverse information and acknowledges Rule 10b5-1/insider-trading attestation language on the form.
Bicara Therapeutics (BCAX) filed a Form 144 disclosing a proposed sale of 10,900 common shares through UBS Financial Services on 10/07/2025 with an aggregate market value of $196,200. The filing lists total outstanding shares of 54,562,841, indicating the sale represents a very small fraction of the company.
The securities were acquired in two non‑qualified option-related transactions: 2,900 shares on 05/12/2024 and 8,000 shares on 10/06/2025, both paid in cash to the issuer. The filer also reported prior sales of 39,600 shares on 10/06/2025 producing gross proceeds of $714,997.10. By signing, the seller represents they have no undisclosed material information.
Bicara Therapeutics Inc. (BCAX) filed a Form 144 notifying a proposed sale of 39,600 common shares through UBS Financial Services on 10/06/2025 with an aggregate market value of $714,997.10. The filing shows two acquisition dates: 05/12/2024 for 15,600 shares from a nonqualified option exercise paid in cash, and 10/06/2025 for 24,000 shares from an NQSO also paid in cash. The total outstanding shares reported are 54,562,841, which places the proposed sale at roughly 0.07% of outstanding common stock. No sales by the reporting person in the prior three months were reported, and the filer states they are not aware of any undisclosed material adverse information.
Bicara Therapeutics, Inc. (BCAX) filed a Form 144 notifying a proposed sale of 6,514 common shares, with an aggregate market value of $110,998, listing the intended sale date as 10/06/2025 on NASDAQ. The filing shows these shares were acquired and paid for on 10/06/2025 through the exercise of stock options from the issuer, with payment in cash. The filer reports no securities sold in the prior three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Bicara Therapeutics, Inc. (BCAX) has filed a registration statement on Form S-3 establishing a shelf for securities and incorporates by reference prior SEC filings including its Form 10-K and amendments. The prospectus discloses clinical data for an HPV-negative HNSCC population with a PD-L1 combined positive score ≥1 and reports a 2-year overall survival rate of 46%. The document describes tax and withholding rules for non-U.S. holders, including a 30% default U.S. withholding rate and treaty-reduced rates where applicable. The filing lists underwriting and sales agreements, corporate charters and bylaws, opinions from Goodwin Procter LLP, consent from KPMG LLP, and trustee eligibility statements. Multiple exhibits and effective dates, including signatures dated October 3, 2025, are included.
Lara Meisner, Chief Legal Officer of Bicara Therapeutics (BCAX), reported option exercise and an immediate sale on 09/29/2025 under a pre-established plan. The reporting person exercised a stock option with a $9.2435 exercise price to acquire 33,807 shares and concurrently sold 33,807 shares at $14.75 per share, leaving 0 shares of common stock held directly after the sale. The option granting those shares vests on a schedule that began with a 25% vesting on 08/13/2025 and continues in twelve equal quarterly installments; the option expires 08/13/2034. The filing notes the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted November 13, 2024.
Bicara Therapeutics (BCAX) Form 144 reports a proposed sale of 33,807 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $395,879.97, representing part of the issuer's outstanding 54,562,841 shares. The shares were acquired and will be sold on 09/29/2025 upon exercise of stock options, with payment in cash. The filing also discloses 10b5-1 plan sales by Lara Meisner of 15,829 shares on 09/15/2025 for gross proceeds of $181,893.96. The filer attests there is no undisclosed material adverse information and includes standard Rule 144 and 10b5-1 representations.
Lara Meisner, Chief Legal Officer and director of Bicara Therapeutics (BCAX), reported insider transactions on 09/15/2025 executed under a Rule 10b5-1 trading plan adopted on 11/13/2024. She acquired 15,829 shares of Common Stock at an exercise price of $5.45 and simultaneously sold 15,829 shares at a weighted-average price of $11.49, with sale prices ranging from $11.34 to $11.73.
The filing also discloses two stock option grants exercisable at $5.45 that were affected by the transactions: one covering 6,085 underlying shares and another covering 9,744 underlying shares, each with vesting schedules described in the filing and expiration dates of 12/14/2033.